Skip to content

Artificial Intelligence System for Early Warning of Adverse Events in Acute Myocardial Infarction

Artificial Intelligence System for Early Warning of Adverse Events in Acute Myocardial Infarction

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07139860
Acronym
AIEWAEAMI
Enrollment
1400
Registered
2025-08-24
Start date
2022-11-26
Completion date
2026-12-31
Last updated
2025-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction With ST Elevation, Early Warning, Intelligent Management Platform

Brief summary

The goal of this observational study is to learn about the effectiveness of an artificial intelligence-based early warning system for predicting adverse events in patients with acute myocardial infarction (AMI). The main question it aims to answer is: Does an AI-based early warning system improve the assessment and prediction of adverse events across the full course of AMI care (from prevention to diagnosis, treatment, and rehabilitation)? Participants who are receiving routine medical care for AMI in tertiary hospitals will have their multimodal medical data (clinical records, diagnostic tests, imaging, treatment pathways) collected and analyzed. Data will be integrated using innovative cross-modal representation methods and predictive models. The study will follow patients during their hospital stay and subsequent clinical follow-up to evaluate the feasibility, accuracy, and clinical value of the AI-based early warning system.

Interventions

None listed

Sponsors

Hui Chen
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* 1\. Hospitalized patients who meet the diagnostic criteria for acute myocardial infarction. 2. Patients who agree to participate and sign the informed consent form.

Exclusion criteria

* 1\. Patients with terminal malignant tumors and an expected survival time of less than 3 months. 2. Patients with complete disability and inability to communicate. 3. Patients unable to comply with follow-up.

Design outcomes

Primary

MeasureTime frameDescription
MACCE1-3 yearsCardiac death All-cause mortality Malignant arrhythmia Non-fatal recurrent myocardial infarction Non-fatal stroke Unplanned repeat revascularization Rehospitalization for heart failure

Countries

China

Contacts

Primary ContactHui Chen
13910710028@163.com+86 13910710028

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026